Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Schaffer

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
Journal of Neuroscience Methods|September 4, 2017
Extended, continuous measures of functional status in community dwelling persons with Alzheimer's and related dementia: Infrastructure, performance, tradeoffs, preliminary data, and promiseBradley Zylstra, George Netscher, Julien Jacquemot, et al.
Translational Oncology|January 5, 2021
Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformationBrendan P Hodkinson, Michael Schaffer, Joshua D Brody, et al.
Alzheimer'S & Dementia (New York, N. Y.)|June 18, 2020
Long-term digital device-enabled monitoring of functional status: Implications for management of persons with Alzheimer's diseaseNatalie A Manley, Eléonore Bayen, Tamara L Braley, et al.
Nature Medicine|May 6, 2024
Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trialJordi Rodón, Silvia Damian, Muhammad Furqan, et al.
Nature Medicine|May 24, 2024
Publisher Correction: Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trialJordi Rodón, Silvia Damian, Muhammad Furqan, et al.
British Journal of Haematology|May 4, 2021
Comparison of immunohistochemistry and gene expression profiling subtyping for diffuse large B-cell lymphoma in the phase III clinical trial of R-CHOP ± ibrutinibSriram Balasubramanian, Songbai Wang, Christopher Major, et al.
BMC Bioinformatics|March 8, 2020
CNV Radar: an improved method for somatic copy number alteration characterization in oncologyDavid Soong, Jeran Stratford, Herve Avet-Loiseau, et al.
Leukemia|August 13, 2022
Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trialCiara L Freeman, Prasath Pararajalingam, Ling Jin, et al.
Blood Advances|September 9, 2021
Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumabAlessio Bruscaggin, Lodovico Terzi di Bergamo, Valeria Spina, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 9, 2016
Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor-Positive Metastatic Breast CancerWeimin Li, Joyce O'Shaughnessy, Daniel Hayes, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
Journal of Neuroscience Methods|September 4, 2017
Extended, continuous measures of functional status in community dwelling persons with Alzheimer's and related dementia: Infrastructure, performance, tradeoffs, preliminary data, and promiseBradley Zylstra, George Netscher, Julien Jacquemot, et al.
Translational Oncology|January 5, 2021
Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformationBrendan P Hodkinson, Michael Schaffer, Joshua D Brody, et al.
Alzheimer'S & Dementia (New York, N. Y.)|June 18, 2020
Long-term digital device-enabled monitoring of functional status: Implications for management of persons with Alzheimer's diseaseNatalie A Manley, Eléonore Bayen, Tamara L Braley, et al.
Nature Medicine|May 6, 2024
Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trialJordi Rodón, Silvia Damian, Muhammad Furqan, et al.
Nature Medicine|May 24, 2024
Publisher Correction: Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trialJordi Rodón, Silvia Damian, Muhammad Furqan, et al.
British Journal of Haematology|May 4, 2021
Comparison of immunohistochemistry and gene expression profiling subtyping for diffuse large B-cell lymphoma in the phase III clinical trial of R-CHOP ± ibrutinibSriram Balasubramanian, Songbai Wang, Christopher Major, et al.
BMC Bioinformatics|March 8, 2020
CNV Radar: an improved method for somatic copy number alteration characterization in oncologyDavid Soong, Jeran Stratford, Herve Avet-Loiseau, et al.
Leukemia|August 13, 2022
Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trialCiara L Freeman, Prasath Pararajalingam, Ling Jin, et al.
Blood Advances|September 9, 2021
Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumabAlessio Bruscaggin, Lodovico Terzi di Bergamo, Valeria Spina, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 9, 2016
Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor-Positive Metastatic Breast CancerWeimin Li, Joyce O'Shaughnessy, Daniel Hayes, et al.
Pageof 6